Clinical Trial Update: Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD [NA]

View source ↗

Summary

Ongoing clinical trial evaluating TOTUM-448 for reducing liver fat and improving metabolic risk factors in MASLD, with current recruitment status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• TOTUM-448

Snippet

Sponsor: Valbiotis | Conditions: Non-Alcoholic Fatty Liver Disease | NA | Status: RECRUITING